Issue link: https://www.e-digitaleditions.com/i/1267517
6 July 2020 Tablets & Capsules correction In the May 2020 issue of Tablets & Capsules, we misspelled the company name and website for the DeltaVita 1 dual-centrifuge bead mill on page 23. The correct contact information is: Netzsch, Exton, PA 484 879 2020 www.netzsch-grinding.com markets Pharmaceutical packaging market to grow at 6 percent through 2027 PUNE, India—The global phar- maceutical packaging market is fore- cast to grow at a compound annual rate of 6 percent and will be worth $142.59 billion by 2027, according to Fortune Business Insights. The overall growth of the global phar- maceutical industry and the increas- ing adoption of generic drugs in developing countries will drive market growth. Packaging for oral drug delivery, which includes tab- lets, capsules, powders, liquids, and semi-liquids, dominates the market, with flexibility in dosage design and cost-effective production driving growth in the oral drug delivery seg- ment. Market leaders include Amcor, Gerresheimer, Origin Pharma Pack- aging, Nelipak Healthcare, Pharma Packaging Solutions, Schott, Bec- ton Dickinson, West Pharmaceutical Services, WestRock, Aptar, Berry, Nipro, Carcano Antonio, Sabic, Lonza, Alpla-Werke Alwin Lehner, Constantia Flexibles, CCL Industries, Frank Noe Egypt, and Gaplast. Global pharmaceutical drug delivery market to reach $1,733 billion by 2026 Portland, OR—The pharmaceuti- cal drug delivery market is expected to reach $1,733 billion by 2026, growing at a compound annual rate of 4.7 percent through 2026, according to a report by Allied Mar- ket Research. Major factors that will contribute to market growth include the rise in healthcare expenditures, increasing governmental support for drug delivery research, and a grow- ing prevalence of chronic diseases. Prominent market players include Bayer, Becton Dickinson, F. Hoff- mann-La Roche, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, 3M, Pfizer, and Sanofi. industry news FDA publishes 69 PSGs S I L V E R S P R I N G , M D — T h e FDA published 26 new and 43 revised product-specific guidances (PSGs) for developing generic drugs, including treatments for HIV, leukemia, opioid use disor- der, and post-partum depression. PSGs provide recommendations for developing generic drugs and gen- erating the evidence needed for an Abbreviated New Drug Application. Benefit from the galenIQ™ effect. Less bitter, more pleasant. galenIQ™ is pharma-grade Isomalt (Ph. Eur., USP-NF, BP, JP). The easy to use filler-binder that makes medicine taste better.